KingNY-Life
commented on
$Serve Robotics(SERV.US$ I now have 500 shares, at a cost of 14.78, is there still a chance to turn around?
Translated
1
5
KingNY-Life
commented on
$Serve Robotics(SERV.US$ You can ask Wall Street to stop swiping; why don't you just go up to 17
I want to sleep
Translated
8
KingNY-Life
commented on
$TeraWulf(WULF.US$ WHAT HAPPENED? It keeps falling
Translated
2
KingNY-Life
commented on
$Serve Robotics(SERV.US$ Tonight 20
Translated
4
KingNY-Life
commented on
$Serve Robotics(SERV.US$ is it too late to enter. am late to the game
1
6
$CEL-SCI(CVM.US$
https://newsfilter.io/a/f731809300504d2a09e0ca4744b13024
CEL-SCI bias analysis concluded that the demographic and baseline characteristics of the Multikine treatment group and the control group were comparable in the phase 3 study. There were no mixed baseline parameters in the Multikine treatment group and control group. There were no biases in the study, and no biases favorable to the study product Multikine were found. As a result, the study data are reliable, explainable, statistically significant, and have been shown to support the clinical effects of neo-adjuvant (pre-operative) Multikine immunotherapy in extending the lifespan of these patients in phase 3 studies.
This is critical information because CEL-SCI will conduct a confirmatory registration study on 212 patients on Multikine in accordance with FDA approval. The target population of the confirmatory study showed that patients treated with Multikine had a 5-year survival rate of 73% for advanced primary head and neck cancer, compared with 45% in the control group.
https://newsfilter.io/a/f731809300504d2a09e0ca4744b13024
CEL-SCI bias analysis concluded that the demographic and baseline characteristics of the Multikine treatment group and the control group were comparable in the phase 3 study. There were no mixed baseline parameters in the Multikine treatment group and control group. There were no biases in the study, and no biases favorable to the study product Multikine were found. As a result, the study data are reliable, explainable, statistically significant, and have been shown to support the clinical effects of neo-adjuvant (pre-operative) Multikine immunotherapy in extending the lifespan of these patients in phase 3 studies.
This is critical information because CEL-SCI will conduct a confirmatory registration study on 212 patients on Multikine in accordance with FDA approval. The target population of the confirmatory study showed that patients treated with Multikine had a 5-year survival rate of 73% for advanced primary head and neck cancer, compared with 45% in the control group.
Translated
1
KingNY-Life
reacted to
$Serve Robotics(SERV.US$ Influencer stocks in the second half of the year were none other than SERV! This is too fierce, where is the skyline?
Translated
![Picture](https://ussnsimg.moomoo.com/sns_client_feed/70127023/20240726/e53f3f77b1138599a8637ba19aaed3c6.jpg/thumb?area=103&is_public=true)
1
KingNY-Life : Kakura